The U.S. Department of Health and Human Services (HHS) released a statement that they are pausing the distribution of Bamlanivimab/Etesevimab as 11% of the COVID-19 variants identified nationally are resistant to this combination. Both HHS and MDHHS recommend switching Bamlanivimab/Etesevimab to REGN-COV or Sotrovimab.
In response to national and state guidance, Munson Healthcare (MHC) changed its Monoclonal Antibody (mAb) Treatment from Bamlanivimab/Etesevimab to REGN-COV (Casirivimab/Imdevimab) for all patients starting Monday, June 28. Although our local COVID-19 variant prevalence remains low, it is a national mandate to change the drug combination for mAB Therapy based on national data of COVID-19 variant prevalence.
This change does NOT affect MHC’s mAb referral process. Our team will now be ordering the new C/I combo for all mAb patients. The one-time mAb infusion therapy is available for providers to refer their qualifying high-risk COVID-19 positive outpatients or for patients to self-refer, and we currently have many openings available. A reminder that referral resources are available on our COVID-19 For Providers website.
Questions? Call the mAb Support Line at 231-935-4880.